Catalyst
First-in-class muscarinic agonist launch tests payer appetite for novel MOA in psychiatry.
Date
June 18, 2026
Phase
Commercial
Status
upcoming
Signal score
8.1
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.